Reason for request
Inclusion on the list of medicines refundable by National Health Insurance and approved for hospital use.
Clinical Benefit
| Substantial |
The actual benefit of CAPRELSA is substantial. |
Clinical Added Value
| minor |
The transparency Commission considers that CAPRELSA provides a minor improvement in the actual benefit (IAB level IV) in the treatment of aggressive and symptomatic medullary thyroid cancer (MTC) in patients with unresectable locally advanced or metastatic disease. |
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
rzx1eV8HBEbCK4u0
